Recent Updates — JSPRW
On September 30, 2026, Jasper Therapeutics stockholders approved a proposal granting the Board discretion to execute a reverse stock split at any ratio between 1-for-15 and 1-for-35 by December 31, 2026. The vote also authorized an increase in common shares from 490 million to 675 million. Jasper Therapeutics develops therapies for rare diseases.
Jasper Therapeutics completed its acquisition of Kira Pharmaceuticals on July 16, 2026. The transaction involved issuing 5,195,009 shares of common stock and 4,899,439 shares of non-voting convertible preferred stock to Kira shareholders and SAFE holders. Concurrently, Jasper raised approximately $132 million in a private placement of preferred stock. The preliminary purchase price allocation includes $125.2 million for acquired in-process research and development (IPR&D) which was expensed immediately. Additionally, the deal included a contingent value right agreement providing up to $30 million if a Priority Review Voucher is obtained by December 2028, and a license agreement with Mirador Therapeutics granting rights to KP-301 and KP-402 for an upfront payment of $12 million. Jasper Therapeutics operates in the biotechnology industry, focusing on developing immunology therapies.
Jasper Therapeutics received a notice from Nasdaq on August 21, 2026, indicating it no longer meets the minimum stockholders' equity requirement of $2.5 million for continued listing under Listing Rule 5550(b)(1). The company has until October 5, 2026, to submit a compliance plan and anticipates regaining compliance through stockholder approval of converting its Non-Voting Convertible Preferred Stock at an upcoming special meeting. Failure to regain compliance could lead to delisting proceedings before Nasdaq's Hearing Panel. Jasper Therapeutics operates in the biotechnology industry, focusing on developing therapies for rare diseases.
Jasper Therapeutics reported second quarter 2026 financial results and provided a corporate update. The company completed the acquisition of Kira Pharmaceuticals in July 2026 via an all-stock transaction, creating a combined entity with a robust portfolio for immune-mediated diseases. Concurrently, Jasper raised $132 million in gross proceeds through a private placement of non-voting convertible preferred stock. As of June 30, 2026, the company held $7.3 million in cash and reported a net loss of $2.8 million, or $0.10 per share. The combined company plans to advance lead asset KP-104, progress briquilimab toward a potential BLA, and commence first-in-human studies for KP-701. Jasper Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies for immune-mediated diseases.